This site uses technical cookies, Analytics cookies and third-party cookies for the operation of the site and to improve the user experience.
By clicking on Accept, you consent to the use of cookies. Read the information.

Privacy | Cookie Policy

Search

Enter the startup's name

Results

Harrison.ai

At harrison.ai, we believe that high-quality healthcare is a fundamental human right. It should be accessible to all, no matter where we are in the world.

To make this vision a reality, we combine medical insights with industry-leading data engineering and harness the potential of artificial intelligence (AI) to deliver a fairer, brighter future for healthcare.

By bringing together the greatest minds, we’re cultivating a place that encourages outstanding work and bold, new ideas.

Our mission is to create AI-as-a-medical-device solutions through ventures and ultimately improve the standard of healthcare for 1million lives every day.

Categories
Artificial Intelligence
Startup Details
HOJA
Categories
Smart Cities and Mobility
Startup Details
Home Agent

Home Agent is the first 100% home based Contact Center in the Brazilian market, we’ve been reinventing the contact center sector through home office since 2011.
Home Agent, with its Home Office operating model, is inverting the logic of this market, providing its customers with access to a high-quality customer relationship, with economic efficiency and positive social impact. We've been operating this model long before the pandemic happened, as we understand that the asset light model allows for operational flexibility and access to professionals with a profile that traditional companies in this market cannot.

Categories
Smart Cities and Mobility
Startup Details
HysensBio

HysensBio presents a new paradigm for incurable dental diseases with our Dentopine platform, which reactivates poorly functioning or aged tooth cells. Joo Cheol Park, CEO of HysensBio & a professor at Seoul National University School of Dentistry strengthened first-in-class drug development capabilities through 20 years of research and development.
HysensBio is developing two platform technologies, 1) “Dentopine”, first-in-class therapeutics for dental diseases, and 2) “PACA”, Permanent Adult Cell Activation therapeutics for incurable diseases. HysensBio is now conducting Phase 1/2a Clinical Trial for Dentin Hypersensitivity, which has about 1 billion patients and a market worth US$ 250B in 2027 (Frost & Sullivan, 2021).

Categories
Healthcare
Startup Details